GTG to form Strategic Alliance with global testing leader QIAGEN
01 févr. 2023 08h00 HE
|
Genetic Technologies Ltd
MELBOURNE, Australia, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health,...
Quarterly Business Update – December 2022; Sixth Consecutive Quarter of Growth
30 janv. 2023 08h00 HE
|
Genetic Technologies Ltd
MELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,” Company”, “GTG”), a global leader in guidance-driven genomics-based tests in health,...
Genetic Technologies Presented Improved Clinical Colorectal Cancer Risk Prediction Model Integrating Polygenic Risk at ASCOGI Cancer Symposium
24 janv. 2023 08h00 HE
|
Genetic Technologies Ltd
MELBOURNE, Australia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and...
Genetic Technologies Provides Business Update
11 janv. 2023 08h00 HE
|
Genetic Technologies Ltd
MELBOURNE, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,”Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health,...
GeneType published in PLOS ONE – development of polygenic risk scores for cardiovascular diseases and type 2 diabetes
06 déc. 2022 08h00 HE
|
Genetic Technologies Ltd
MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health,...
Webinar - Dr Erika Spaeth to interview A/Prof Charles Siles on risk assessment tests for serious disease
10 nov. 2022 08h00 HE
|
Genetic Technologies Ltd
MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies (ASX:GTG, NASDAQ:GENE), a global leader in guideline driven Genomics based tests in health, wellness and serious disease...
Genetype for Ovarian Cancer Published in Prestigious European Journal of Cancer Prevention
09 nov. 2022 08h00 HE
|
Genetic Technologies Ltd
MELBOURNE, Australia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health,...
Genetic Technologies Announces Q1 FY23 Quarterly Results and Investor Webinar Details
25 oct. 2022 09h14 HE
|
Genetic Technologies Ltd
MELBOURNE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health,...
Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer
29 sept. 2022 08h00 HE
|
Genetic Technologies Ltd
MELBOURNE, Australia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and...
Genetic Technologies Provides Update on US Operations and Payer Engagement
02 sept. 2022 08h00 HE
|
Genetic Technologies Ltd
MELBOURNE, Australia, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”, “GENE”), a global leader in guideline driven genomics-based tests in...